Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF V600E
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks (New C3)
trametinib + dabrafenib + PDR001
Sensitive
:
C2
Nat Med - 2wk
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks
trametinib + dabrafenib + PDR001
Sensitive
:
C2
Nat Med - 2 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
ASCO-GI 2023 - 3 weeks (New C3)
cetuximab + trametinib + dabrafenib
Sensitive
:
A2
ASCO-GI 2023 - 3wk
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
ASCO-GI 2023 - 3 weeks
cetuximab + trametinib + dabrafenib
Sensitive
:
A2
ASCO-GI 2023 - 3 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks (New C3)
cetuximab + encorafenib
Sensitive
:
A1
ASCO-GI 2023 - 3wk
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks
cetuximab + encorafenib
Sensitive
:
A1
ASCO-GI 2023 - 3 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 3 weeks (New C3)
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 3wk
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 3 weeks
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 3 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600E
Solid Tumor
BRAF V600E
Solid Tumor
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
BRAF V600E
Glioblastoma
BRAF V600E
Glioblastoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
BRAF V600E
Neuroendocrine Tumor
BRAF V600E
Neuroendocrine Tumor
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Biliary Tract Cancer
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Glioma
BRAF V600E
Glioma
selumetinib
Sensitive: A2 - Guideline
selumetinib
Sensitive
:
A2
selumetinib
Sensitive: A2 - Guideline
selumetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
trametinib
Sensitive: A2 - Guideline
trametinib
Sensitive
:
A2
trametinib
Sensitive: A2 - Guideline
trametinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
trametinib
Sensitive: A2 - Guideline
trametinib
Sensitive
:
A2
trametinib
Sensitive: A2 - Guideline
trametinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
BRAF V600E
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
BRAF V600E
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login